All lobbying filings

RARE DISEASE COMPANY COALITION

Lobbying for RARE DISEASE COMPANY COALITION · Healthcare

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · District of Columbia · House · Senate · $70,000.00 expenses · posted Jul 18, 2025

Official filing document

Bills named in this filing 4

HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
HR 1262
Mikaela Naylon Give Kids a Chance Act
HR 946
ORPHAN Cures Act
HR 1414
Cameron’s Law

Lobbying activity 4

Budget/Appropriations

HR 1 - Big Beautiful Bill Act

Pharmacy

HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law FDA Regulatory Priorities

Science/Technology

Executive Order 14297 - Impact of EO on Rare Disease Innovation Rare Disease Policy

Trade (domestic/foreign)

Sec. 232 Pharmaceutical Tariffs

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.